SG11201400289SA - Glycosylated polypeptide and drug composition containing said polypeptide - Google Patents
Glycosylated polypeptide and drug composition containing said polypeptideInfo
- Publication number
- SG11201400289SA SG11201400289SA SG11201400289SA SG11201400289SA SG11201400289SA SG 11201400289S A SG11201400289S A SG 11201400289SA SG 11201400289S A SG11201400289S A SG 11201400289SA SG 11201400289S A SG11201400289S A SG 11201400289SA SG 11201400289S A SG11201400289S A SG 11201400289SA
- Authority
- SG
- Singapore
- Prior art keywords
- polypeptide
- composition containing
- drug composition
- glycosylated
- glycosylated polypeptide
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
- C07K14/6555—Somatostatins at least 1 amino acid in D-form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/655—Somatostatins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2011192202 | 2011-09-04 | ||
| PCT/JP2012/072380 WO2013032011A1 (ja) | 2011-09-04 | 2012-09-03 | 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201400289SA true SG11201400289SA (en) | 2014-05-29 |
Family
ID=47756483
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201400289SA SG11201400289SA (en) | 2011-09-04 | 2012-09-03 | Glycosylated polypeptide and drug composition containing said polypeptide |
| SG10201601324VA SG10201601324VA (en) | 2011-09-04 | 2012-09-03 | Glycosylated polypeptide and drug composition containing said polypeptide |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201601324VA SG10201601324VA (en) | 2011-09-04 | 2012-09-03 | Glycosylated polypeptide and drug composition containing said polypeptide |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US9422357B2 (da) |
| EP (1) | EP2752424B1 (da) |
| JP (1) | JP6178238B2 (da) |
| KR (1) | KR102031998B1 (da) |
| CN (2) | CN103930441B (da) |
| AU (1) | AU2012302636B2 (da) |
| BR (1) | BR112014004784A2 (da) |
| CA (1) | CA2847334C (da) |
| DK (1) | DK2752424T3 (da) |
| IN (1) | IN2014CN02399A (da) |
| RU (1) | RU2624034C2 (da) |
| SG (2) | SG11201400289SA (da) |
| TW (1) | TWI662966B (da) |
| WO (1) | WO2013032011A1 (da) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013032011A1 (ja) * | 2011-09-04 | 2013-03-07 | 株式会社糖鎖工学研究所 | 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物 |
| EP2752425A4 (en) | 2011-09-04 | 2015-04-22 | Glytech Inc | GLYCOSYLATED POLYPEPTIDE AND MEDICAMENT COMPOSITION WITH THIS POLYPEPTIDE |
| CN111855827B (zh) * | 2019-04-24 | 2022-09-16 | 岛津企业管理（中国）有限公司 | 多糖蛋白结合疫苗中多糖蛋白结合位点结合率的测定方法 |
Family Cites Families (35)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4000259A (en) * | 1975-06-16 | 1976-12-28 | American Home Products Corporation | Cyclic dodecapeptide analogs of somatostatin and intermediates |
| US4380953A (en) | 1978-09-11 | 1983-04-26 | Filper Corporation | Transfer mechanism in a peach pitter |
| US4310518A (en) | 1979-10-31 | 1982-01-12 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
| US4235886A (en) | 1979-10-31 | 1980-11-25 | Merck & Co., Inc. | Cyclic hexapeptide somatostatin analogs |
| US4280953A (en) * | 1979-11-08 | 1981-07-28 | The Salk Institute For Biological Studies | Glycosylated analogs of somatostatin |
| US4316891A (en) * | 1980-06-14 | 1982-02-23 | The Salk Institute For Biological Studies | Extended N-terminal somatostatin |
| LU85269A1 (fr) | 1984-03-26 | 1985-10-14 | Techland S A | Composes nouveaux de somatostatine,procede pour leur synthese,preparation a usage veterinaire contenant lesdits composes et procede pour le traitement d'animaux |
| US4801575A (en) * | 1986-07-30 | 1989-01-31 | The Regents Of The University Of California | Chimeric peptides for neuropeptide delivery through the blood-brain barrier |
| HU906340D0 (en) | 1986-10-13 | 1991-04-29 | Sandoz Ag | Synthesis in solid phase for producing peptonic alcohols |
| PH30995A (en) | 1989-07-07 | 1997-12-23 | Novartis Inc | Sustained release formulations of water soluble peptides. |
| WO1997007205A1 (en) * | 1995-08-11 | 1997-02-27 | Novo Nordisk A/S | Method for preparing polypeptide variants |
| US5750499A (en) * | 1995-10-18 | 1998-05-12 | The Salk Institute For Biological Studies | Receptor-selective somatostatin analogs |
| FI965181A (fi) | 1996-12-20 | 1998-06-21 | Map Medical Technologies Oy | Polyalkoholi-peptidijohdannaiset |
| JP3385947B2 (ja) | 1998-01-05 | 2003-03-10 | 松下電器産業株式会社 | バルクフィーダ |
| AU5805500A (en) * | 1999-07-07 | 2001-01-30 | Maxygen Aps | A method for preparing modified polypeptides |
| US20030036181A1 (en) * | 2000-06-30 | 2003-02-20 | Okkels Jens Sigurd | Peptide extended glycosylated polypeptides |
| EP1381396B1 (en) * | 2001-04-23 | 2009-04-01 | Mallinckrodt Inc. | Tc and re labeled radioactive glycosylated octreotide derivatives |
| WO2003008431A1 (fr) | 2001-06-19 | 2003-01-30 | Otsuka Chemical Co.,Ltd. | Methode de production d'un derive d'asparagine de chaines des sucres |
| US7943763B2 (en) | 2002-07-05 | 2011-05-17 | Otsuka Chemical Holdings Co., Ltd. | Process for preparing glycopeptides having asparagine-linked oligosaccharides, and the glycopeptides |
| TWI330641B (en) | 2002-12-24 | 2010-09-21 | Yasuhiro Kajihara | Sugar chain asparagine derivatives |
| CN100413889C (zh) * | 2002-12-24 | 2008-08-27 | 大塚化学株式会社 | 糖链天冬酰胺衍生物、糖链天冬酰胺和糖链以及它们的制造方法 |
| KR100661212B1 (ko) | 2002-12-26 | 2007-04-16 | 오츠카 가가쿠 가부시키가이샤 | 3분지형 당사슬 아스파라긴 유도체, 상기 당사슬아스파라긴, 상기 당사슬 및 그들의 제조방법 |
| CA2514337C (en) | 2003-02-04 | 2010-07-13 | Otsuka Chemical Co., Ltd. | Process for producing sugar chain asparagine derivative |
| WO2004101619A1 (ja) * | 2003-05-15 | 2004-11-25 | Shionogi Co., Ltd. | 機能的糖ペプチドの合理的設計および合成 |
| KR100731875B1 (ko) | 2003-07-28 | 2007-06-25 | 오츠카 가가쿠 가부시키가이샤 | 아미노화 복합형 당사슬 유도체 및 그의 제조방법 |
| KR100604994B1 (ko) * | 2004-01-30 | 2006-07-26 | 한국생명공학연구원 | 알파1,6-만노실트랜스퍼라제를 코딩하는 한세눌라폴리모르파 기원의 신규 유전자 및 상기 유전자가 결손된한세눌라 폴리모르파 변이주를 이용한 재조합 당단백질생산 방법 |
| TWI466897B (zh) | 2005-07-19 | 2015-01-01 | Glytech Inc | 癌細胞之檢測方法、糖鏈之構造解析方法，以及糖鏈衍生物 |
| US20070025910A1 (en) * | 2005-07-29 | 2007-02-01 | Norenberg Jeffrey P | Anticancer therapy |
| EP1941902A1 (en) * | 2007-01-02 | 2008-07-09 | Novartis AG | Use of Somatostatin analogs in cluster headache |
| AU2008264750C1 (en) * | 2007-06-19 | 2013-01-10 | Glytech, Inc. | GLP-1 peptide having sugar chain attached thereto |
| US20110172165A1 (en) | 2008-02-19 | 2011-07-14 | Peter Artymiuk | Modified linkers |
| AU2009261441B2 (en) * | 2008-06-17 | 2013-01-10 | Glytech, Inc. | Oligosaccharide chain added glp-1 peptide |
| WO2009156511A2 (en) * | 2008-06-27 | 2009-12-30 | Novo Nordisk A/S | N-glycosylated human growth hormone with prolonged circulatory half-life |
| EP2752425A4 (en) | 2011-09-04 | 2015-04-22 | Glytech Inc | GLYCOSYLATED POLYPEPTIDE AND MEDICAMENT COMPOSITION WITH THIS POLYPEPTIDE |
| WO2013032011A1 (ja) * | 2011-09-04 | 2013-03-07 | 株式会社糖鎖工学研究所 | 糖鎖付加ポリペプチドおよび当該ポリペプチドを含む医薬組成物 |
-
2012
- 2012-09-03 WO PCT/JP2012/072380 patent/WO2013032011A1/ja active Application Filing
- 2012-09-03 CN CN201280053754.2A patent/CN103930441B/zh active Active
- 2012-09-03 US US14/342,359 patent/US9422357B2/en active Active
- 2012-09-03 KR KR1020147008130A patent/KR102031998B1/ko active IP Right Grant
- 2012-09-03 AU AU2012302636A patent/AU2012302636B2/en active Active
- 2012-09-03 SG SG11201400289SA patent/SG11201400289SA/en unknown
- 2012-09-03 RU RU2014112046A patent/RU2624034C2/ru active
- 2012-09-03 BR BR112014004784A patent/BR112014004784A2/pt not_active Application Discontinuation
- 2012-09-03 IN IN2399CHN2014 patent/IN2014CN02399A/en unknown
- 2012-09-03 CA CA2847334A patent/CA2847334C/en active Active
- 2012-09-03 CN CN201710964257.2A patent/CN107522779B/zh active Active
- 2012-09-03 EP EP12828271.2A patent/EP2752424B1/en active Active
- 2012-09-03 SG SG10201601324VA patent/SG10201601324VA/en unknown
- 2012-09-03 DK DK12828271T patent/DK2752424T3/da active
- 2012-09-03 JP JP2013531454A patent/JP6178238B2/ja active Active
- 2012-09-04 TW TW101132259A patent/TWI662966B/zh active
-
2016
- 2016-07-08 US US15/205,960 patent/US9937264B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2847334C (en) | 2020-09-01 |
| TWI662966B (zh) | 2019-06-21 |
| JP6178238B2 (ja) | 2017-08-09 |
| EP2752424B1 (en) | 2019-09-11 |
| CA2847334A1 (en) | 2013-03-07 |
| CN103930441A (zh) | 2014-07-16 |
| KR20140059829A (ko) | 2014-05-16 |
| IN2014CN02399A (da) | 2015-06-19 |
| KR102031998B1 (ko) | 2019-10-14 |
| WO2013032011A1 (ja) | 2013-03-07 |
| EP2752424A1 (en) | 2014-07-09 |
| US9422357B2 (en) | 2016-08-23 |
| AU2012302636B2 (en) | 2016-09-15 |
| CN107522779A (zh) | 2017-12-29 |
| CN103930441B (zh) | 2017-11-17 |
| SG10201601324VA (en) | 2016-03-30 |
| CN107522779B (zh) | 2021-10-26 |
| BR112014004784A2 (pt) | 2017-03-21 |
| US9937264B2 (en) | 2018-04-10 |
| RU2624034C2 (ru) | 2017-06-30 |
| TW201315478A (zh) | 2013-04-16 |
| DK2752424T3 (da) | 2019-11-18 |
| AU2012302636A1 (en) | 2014-03-20 |
| EP2752424A4 (en) | 2015-04-22 |
| US20170157260A1 (en) | 2017-06-08 |
| RU2014112046A (ru) | 2015-11-27 |
| US20140336116A1 (en) | 2014-11-13 |
| JPWO2013032011A1 (ja) | 2015-03-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL262667B (en) | An isolated polynucleotide encoding a polypeptide and a pharmaceutical composition containing the isolated polynucleotide | |
| SG10201601327RA (en) | Glycosylated polypeptide and drug composition containing said polypeptide | |
| HK1199889A1 (en) | Relaxin fusion polypeptides and uses thereof | |
| ZA201305504B (en) | Compositions containing glycosylated antibodies and uses thereof | |
| IL279676A (en) | Recombinant proteins and therapeutic uses | |
| EP2728002A4 (en) | HETERODIMIZED POLYPEPTIDE | |
| EP2718317A4 (en) | GLUCOSE-DEPENDENT INSULINOTROPE POLYPEPTIDE ANALOGUE, PHARMACEUTICAL COMPOSITIONS AND THEIR USE | |
| EP2738255A4 (en) | PEPTIDE FROM ERAP1 AND ITS USE | |
| SG11201405578TA (en) | Pharmaceutical composition containing peptide | |
| ZA201302113B (en) | Caspofungin composition | |
| EP2718283A4 (en) | INDAZOLE AND PYRROLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | |
| EP2775831A4 (en) | PHARMACEUTICAL COMPOSITIONS AND USES THEREOF | |
| ZA201207375B (en) | Stabilized pharmaceutical composition | |
| SG11201402139UA (en) | High mast2-affinity polypeptides and uses thereof | |
| EP2666482A4 (en) | PARTICLE COMPOSITION AND PHARMACEUTICAL COMPOSITION WITH PARTICLE COMPOSITION | |
| HK1198910A1 (en) | Pharmaceutical composition comprising ebastine and fluticasone | |
| SG11201400289SA (en) | Glycosylated polypeptide and drug composition containing said polypeptide | |
| SG11201401071YA (en) | Glycosylated polypeptide and pharmaceutical composition containing same | |
| IL221501A (en) | Medicinal product containing miramistine | |
| EP2743252A4 (en) | TETRAVALENT PLATINUM COMPLEX AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | |
| PL2918267T3 (pl) | Kompozycja farmaceutyczna w postaci cząstek stałych | |
| EP2751129A4 (en) | PROTEIN P14 WITH CANCER, ANTIALLERGIC EFFECT AND PHARMACEUTICAL COMPOSITION THEREWITH | |
| ZA201309537B (en) | Pharmaceutical composition comprising fexofedine |